Stock Ratings / Health Care / INM / financials

PTN (38) CMMB (38) MBRX (43) ENSC (35) ⌘ Pro Terminal →

InMed Pharmaceuticals Inc. (INM) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.63 +1.61% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.63

InMed Pharmaceuticals Inc. (INM) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $8.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.63 (+0.10%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-4.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INM)Realized 20D OHLCV Swing Band: ±11.6%

Deterministic 5-Pillar Attribution (47/100 Composite)

🔍 WHY INM SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (28% of score)

FRED Regime × Technicals: 60% of 52W Range • RSI-14 at 69.8 (BULLISH MOMENTUM)

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (26% of score)

20D Institutional Volume Accumulation (±11.6% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.36-2.9% Next Q

Q2 (-2Q)

Grade D$1.32+9.1% Next Q

Q3 (-1Q)

Grade D$1.44+13.2% Next Q

Current

Grade D$1.63-5.9% Hist 90D α

Trajectory: E (39) → D (47)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a INM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While INM currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.38) and Max Pain ($1.71) forces dealer call-delta covering toward $2.45.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “INM Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 47%NO 53%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How INM Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.1M

FY24

Rev $4.6M

FY25

Rev $4.9M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.9M	34.5%	0%	-$8.2M	-$8.1M	-35%
FY 2024	$4.6M	23.9%	0%	-$7.7M	-$7.0M	-35%
FY 2023	$4.1M	34.5%	-80%	-$7.9M	-$7.3M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INM)

✓Walkthrough of INM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +126.39%⚡ TESTING RESISTANCE

2026-10-30O $1.55H $1.63L $1.51C $1.63VOL 36.7K

RES: $1.68SUP: $1.15SMA50: $1.38SMA200: $1.20

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INM Butterfly Map → + Track INM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +7.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INM)

Health Care Rank #426 of 1016 ⚔️ PTN vs INM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INM vs. PTN, CMMB, MBRX, ENSC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, InMed Pharmaceuticals Inc. (INM) ranks #426 by composite RQD confidence (47/100, grade D) and #903 by equity capitalization ($8.9M). Within this direct 5-issuer industry benchmark cohort, INM leads on earnings valuation at N/A trailing P/E, while INM leads on capital efficiency and profitability with -35.0% ROIC and 34.5% gross margin. INM currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INM ACTIVE InMed Pharmaceuticals Inc.	D	47/100	—	34.5%	-35.0%	+1.61%	$8.9M	Benchmark Subject
PTN Palatin Technologies Inc.	D-	38/100	—	—	-35.0%	-3.33%	$8.8M	/ptn-vs-inm →
CMMB Chemomab Therapeutics Ltd.	D-	38/100	—	—	-35.0%	-0.91%	$8.8M	/cmmb-vs-inm →
MBRX Moleculin Biotech Inc.	D-	43/100	—	—	-35.0%	-0.29%	$9.2M	/mbrx-vs-inm →
ENSC Ensysce Biosciences Inc.	D-	35/100	—	—	-35.0%	-3.16%	$8.5M	/ensc-vs-inm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001728328

In its most recent audited fiscal period (FY2025, filed 2025-06-30), InMed Pharmaceuticals Inc. (INM) reported GAAP revenue of $4.9M (+7.5% vs. FY2024 revenue of $4.6M , and +19.5% cumulative change since FY2023) , GAAP net income of -$8.2M, operating cash flow of -$8.1M, and free cash flow of -$8.1M (-15.8% YoY). On the balance sheet, INM closed FY2025 with $11.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$4.9M	-$8.2M	-$8.1M	-$8.1M	$11.2M	—
FY2024 (FY)	2024-06-30	$4.6M	-$7.7M	-$7.0M	-$7.0M	$8.5M	—
FY2023 (FY)	2023-06-30	$4.1M	-$7.9M	-$7.3M	-$7.3M	—	—

3. INM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, InMed Pharmaceuticals Inc. (NASDAQ: INM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.63 (+1.61% 1D, market cap $8.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, INM ranks #426 in composite RQD confidence.

How does INM compare to PTN and CMMB in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INM carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 34.5%, and ROIC of -35.0%. By comparison, PTN (Palatin Technologies Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $8.8M) and CMMB (Chemomab Therapeutics Ltd.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $8.8M). Among the 5-stock peer group, INM leads on earnings multiple (N/A) while INM leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INM?

Per INM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001728328), InMed Pharmaceuticals Inc. generated $4.9M in revenue (+7.5% YoY), -$8.2M in net income, and -$8.1M in free cash flow against $11.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INM trading relative to its 50-day, 200-day, and 52-week technical levels?

INM last traded at $1.63 (+1.61% on volume of 37,397 shares), positioning the stock +18.12% above its 50-day simple moving average ($1.38) and +35.83% above its 200-day simple moving average ($1.20). Across its 52-week range of $0.57 to $2.33, INM sits at the 60.2% percentile with a 14-day RSI of 69.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.6% ($1.44 to $1.82).

INM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is InMed Pharmaceuticals Inc. (INM)?

In FY 2025 (10-K), INM converted $4.9M of revenue into a 34.5% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: INM RQD Cockpit INM 12M Forecast INM Earnings & Move INM Dividends & DRIP INM Insiders & 13F INM Whale Options INM Profit Sankey INM News & Why